These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15170741)

  • 1. Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
    Gonzalez S; Naranjo A; Serrano LM; Chang WC; Wright CL; Jensen MC
    J Gene Med; 2004 Jun; 6(6):704-11. PubMed ID: 15170741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
    Jensen MC; Cooper LJ; Wu AM; Forman SJ; Raubitschek A
    Cytotherapy; 2003; 5(2):131-8. PubMed ID: 12745575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Park JR; Digiusto DL; Slovak M; Wright C; Naranjo A; Wagner J; Meechoovet HB; Bautista C; Chang WC; Ostberg JR; Jensen MC
    Mol Ther; 2007 Apr; 15(4):825-33. PubMed ID: 17299405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
    Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
    J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U; Klundt E; Groner B
    J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
    Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
    Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
    Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
    Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
    Moeller M; Haynes NM; Trapani JA; Teng MW; Jackson JT; Tanner JE; Cerutti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    Cancer Gene Ther; 2004 May; 11(5):371-9. PubMed ID: 15060573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
    Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
    Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The T-body approach: redirecting T cells with antibody specificity.
    Eshhar Z
    Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.
    Weijtens ME; Willemsen RA; Valerio D; Stam K; Bolhuis RL
    J Immunol; 1996 Jul; 157(2):836-43. PubMed ID: 8752936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
    Hombach A; Hombach AA; Abken H
    Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
    Birkholz K; Hombach A; Krug C; Reuter S; Kershaw M; Kämpgen E; Schuler G; Abken H; Schaft N; Dörrie J
    Gene Ther; 2009 May; 16(5):596-604. PubMed ID: 19158846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.